Drainage of Tumor-Derived DNA into Sentinel Lymph Nodes in Breast Cancer Patients

• Published in: Pathology oncology research Vol. 25; no. 4; pp. 1635 - 1643
• Main Authors: Miyamura, Yukiko, Kagara, Naofumi, Miyake, Tomohiro, Tanei, Tomonori, Naoi, Yasuto, Shimoda, Masafumi, Shimazu, Kenzo, Kim, Seung Jin, Noguchi, Shinzaburo
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.10.2019; Springer Nature B.V
• Subjects: Apoptosis; Assaying; Biomarkers, Tumor - genetics; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer Research; Carcinoma, Ductal, Breast - genetics; Carcinoma, Ductal, Breast - pathology; Carcinoma, Lobular - genetics; Carcinoma, Lobular - pathology; Circulating Tumor DNA - genetics; Class I Phosphatidylinositol 3-Kinases - genetics; Deoxyribonucleic acid; DNA; Female; Follow-Up Studies; Humans; Immunology; Lymph nodes; Lymphatic system; Metastases; Metastasis; Middle Aged; Mutation; Nucleic acids; Oncology; Original Article; Pathology; Prognosis; Sentinel Lymph Node - pathology; Tumor cells; Tumors; Wound drainage; mutation; Sentinel lymph node; Circulating tumor DNA; Apoptosis; PIK3CA mutation
• ISSN: 1219-4956; 1532-2807
• DOI: 10.1007/s12253-019-00618-z

Circulating tumor DNA (ctDNA) is released from cancer cells by apoptosis or other mechanisms, and as tumor tissue contains both blood and lymphatic vessels, ctDNA can spread to local lymph nodes (LNs). We aimed to detect the tumor-derived free DNA in metastasis-free LNs in patients with breast cancers harboring the PIK3CA- H1047R mutation. One hundred twenty-three patients were evaluated and the PIK3CA- H1047R mutation was assayed in sentinel LNs (SLNs), non-SLNs without metastasis, and serum by digital PCR. The mutant DNA was more frequent in metastasis-free SLNs (21.6%) than in metastasis-free non-SLNs (8.6%; P  = 0.038), and patients with mutation-positive SLNs were more likely to be positive for serum mutant DNA. Apoptosis in primary breast tumors was determined by TUNEL assay. The apoptotic index was significantly higher ( P  = 0.003) in patients with mutation-positive SLNs without metastasis (mean, 1.17%) than those with mutation-negative SLNs without metastasis (mean, 0.79%). It was also significantly higher ( P  = 0.006) in those with mutation-positive serum (mean, 1.41%) than in those with mutation-negative serum (mean, 0.86%). Furthermore, fragment size of PIK3CA- H1047R mutant DNA in metastatic-free SLN lysate used for the one-step nucleic acid amplification (OSNA) assay was short (<500 bp). These results support the theory that DNA is released from the primary tumor via apoptotic fragmentation. In conclusion, ctDNA is detectable in metastasis-free LNs and significantly more frequent in SLNs from patients with breast tumors harboring a high apoptotic index, consistent with drainage of ctDNA from apoptotic primary tumor cells into SLNs.